Skip to main content

Mitosol Side Effects

Generic name: mitomycin ophthalmic

Medically reviewed by Last updated on Nov 22, 2023.

Note: This document contains side effect information about mitomycin ophthalmic. Some dosage forms listed on this page may not apply to the brand name Mitosol.

Applies to mitomycin ophthalmic: ophthalmic powder for solution. Other dosage forms:

Serious side effects of Mitosol

Along with its needed effects, mitomycin ophthalmic (the active ingredient contained in Mitosol) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking mitomycin ophthalmic:

Incidence not known

Other side effects of Mitosol

Some side effects of mitomycin ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

For Healthcare Professionals

Applies to mitomycin ophthalmic: intraocular solution, ophthalmic kit.


The most commonly reported side effects include blebitis, corneal changes, and other localized reactions.[Ref]


Frequency not reported: Blebitis, bleb ulceration, chronic bleb leak, encapsulated/cystic bleb, bleb-related infection, conjunctival necrosis, thin-walled bleb, Descemet's detachment, induced astigmatism, corneal epithelial damage, superficial punctate keratitis, endophthalmitis, hypotony, choroidal reaction, choroidal detachment, choroidal reactions, choroidal detachment, choroidal effusion, serious choroidal detachment, suprachoroidal hemorrhage, hypotony maculopathy, presence of supraciliochoroidal effusion, iritis, cataract development, capsular constriction, posterior synechiae, retinal pigment epithelial tear, serous/rhegatogenous retinal detachment, hyphema, vitreal/retinal/subconjunctival/disk hemorrhage, macular edema, sclera thinning/ulceration, intraocular lens capture, disk swelling, malignant glaucoma, lacrimal drainage system obstruction, ciliary block, corneal vascularization, decreased visual acuity, cystic conjunctival degeneration, upper eyelid retraction, dislocated implants, severe loss of vision, hemiretinal/central retinal vein occlusion[Ref]


Frequency not reported: Wound dehiscence/scleral wound dehiscence[Ref]


Frequency not reported: Blood clot[Ref]


1. Product Information. Mitosol (mitomycin ophthalmic). Mobius Therapeutics. 2012.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.